What is Pharmaron Beijing Co., Ltd.'s (300759.SZ) StockRank?

MoatMap's StockRank for Pharmaron Beijing Co., Ltd. (300759.SZ) is 44/100, with a Hold signal. This is a composite score combining Quality (55), Value (37), and Momentum (43) factor ranks across MoatMap's 20,000+ stock universe.

Does Pharmaron Beijing Co., Ltd. have an economic moat?

Pharmaron Beijing Co., Ltd. (300759.SZ) has a Quality factor score of 55/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Pharmaron Beijing Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Pharmaron Beijing Co., Ltd. (300759.SZ) is Hold, based on a StockRank of 44/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Pharmaron Beijing Co., Ltd. in?

Pharmaron Beijing Co., Ltd. (300759.SZ) operates in the Healthcare sector, specifically the Biotechnology industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

300759.SZ

HOLDFLAG

Pharmaron Beijing Co., Ltd. · Healthcare · China · $6.8B · Avg Vol: $97M/d

StockRank

P/E (TTM)

23.5x

ROE

10.0%

D/E

0.4x

Dividend %

0.9%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Pharmaron Beijing is a leading global CDMO with high-quality capabilities. While it fits the CDMO pricing power theme, it faces severe geopolitical headwinds from US legislative actions (e.g., the Biosecure Act) which threaten its core Western customer base.

COMPANY DESCRIPTION

Pharmaron Beijing Co., Ltd. is a leading global contract research, development, and manufacturing organization (CRO/CDMO) providing end-to-end services for drug discovery and development. The company ranks among the top global players in its sector, offering a fully integrated platform that spans laboratory chemistry, clinical development, and commercial manufacturing. It is characterized by its dual-shore operational model across China, North America, and Europe, serving a highly diversified global biopharma client base.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	1.5B	1.7B	1.8B	2.1B	11.1%
EPS	0.11	0.13	0.15	0.14	6.8%
Shares	1.8B	1.8B	1.8B	1.8B	-0.5%
Debt	904M	1.4B	883M	1.0B	4.8%
Equity	1.6B	1.9B	2.0B	2.2B	12.6%
Op CF	317M	407M	381M	476M	14.6%
Inv CF	-326M	-333M	-299M	-647M	—
Fin CF	-209M	579M	-709M	56M	—

PRICE (1M)-16.5%

SMA 50SMA 200

$3.36

RSI (14)

29.8

52W High

$5.56

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

11.2%76.7

ROE

10.0%71.8

GP/Assets

18.6%43.4

Op. Margin

12.9%71.3

FCF/Assets

-3.8%37.9

Piotroski

—83.4

Int. Cover

10.9x66.0

D/E Ratio

0.41x36.0

Current Ratio

1.08x12.6

Value

P/E (TTM)

23.5x48.4

EV/EBITDA

14.7x28.4

P/FCF

—N/A

P/B

2.5x47.0

P/S

2.8x58.5

Div Yield

0.9%24.5

Momentum

52W High %

60%41.1

RS 6M

-31%40.6

SMA 50/200

0.91x37.8

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+45%51.1

Q Growth

10%52.5

FUNDAMENTALS

Market Cap

$6.8B

P/E (Forward)

16.3x

Gross Margin

34.4%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 300759.SZ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
300759.SZ	Pharmaron Beijing Co., Ltd.(you)	$6.8B	44	HOLD
688428.SS	InnoCare Pharma Limited	$6.4B	40	HOLD
9995.HK	RemeGen Co., Ltd.	$6.3B	40	HOLD
2696.HK	Shanghai Henlius Biotech, Inc.	$4.8B	45	HOLD
600161.SS	Beijing Tiantan Biological Products Co., Ltd.	$4.0B	46	HOLD
002252.SZ	Shanghai RAAS Blood Products Co., Ltd.	$5.2B	34	SELL
002653.SZ	Haisco Pharmaceutical Group Co., Ltd.	$8.5B	56	HOLD
301301.SZ	Yili Chuanning Biotechnology Co.,Ltd.	$2.9B	45	HOLD
603392.SS	Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.	$6.5B	22	SELL
688319.SS	Chengdu Olymvax Biopharmaceuticals Inc.	$2.1B	43	HOLD

Peer medians: ROE 4.7% · P/E 27.9x · Gross margin 53.2%

Pharmaron Beijing Co., Ltd. (300759.SZ) — Stock Score Summary

Pharmaron Beijing Co., Ltd. (300759.SZ) has a MoatMap StockRank of 44/100 based on Quality (55/100), Value (37/100), and Momentum (43/100) factor scores. The current signal is HOLD. Pharmaron Beijing is a leading global CDMO with high-quality capabilities. While it fits the CDMO pricing power theme, it faces severe geopolitical headwinds from US legislative actions (e.g., the Biosecure Act) which threaten its core Western customer base.

Key Financial Metrics

Price	$3.36
Market Cap	$6.8B
P/E (TTM)	23.55
P/E (Forward)	16.29
Price/Book	2.49
Return on Equity	10.0%
Return on Invested Capital	11.2%
Debt/Equity	41.49
Gross Margin	34.4%
Operating Margin	12.9%
Revenue Growth	15.5%
Dividend Yield	0.9%
Free Cash Flow	$-22M

Pharmaron Beijing Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Pharmaron Beijing Co., Ltd.’s (300759.SZ) StockRank?: MoatMap’s StockRank for Pharmaron Beijing Co., Ltd. (300759.SZ) is 44/100, with a Hold signal. It is a composite of Quality (55), Value (37), and Momentum (43) factor ranks across MoatMap’s 20,000+ stock universe.
Does Pharmaron Beijing Co., Ltd. have an economic moat?: Pharmaron Beijing Co., Ltd. (300759.SZ) has a Quality factor score of 55/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Pharmaron Beijing Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Pharmaron Beijing Co., Ltd. (300759.SZ) is Hold, based on a StockRank of 44/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Pharmaron Beijing Co., Ltd. in?: Pharmaron Beijing Co., Ltd. (300759.SZ) operates in the Healthcare sector, specifically the Biotechnology industry (China).